A meta-analysis of 40 cohort studies highlighted that SGLT2 inhibitors administration was associated with an increased risk of diabetic ketoacidosis (hazard ratio HR 1.21) and genital tract infections (HR 2.72), while these drugs were not associated with an increased risk of lower limb amputation (HR 1.06) or bone fractures (HR 0.99). The gene discussed is SLC5A2; the disease is diabetic ketoacidosis.